Biologic

SAN DIEGO — Older patients with inflammatory bowel disease who were treated with biologics exhibited a lower incidence of dementia compared with those never treated with biologics, according to data presented at Digestive Disease Week 2022.

SAN DIEGO — A novel tool for educating patients with inflammatory bowel disease on biologic therapies failed to improve upon standard education with regard to shared decision-making, according to data presented at Digestive Diseases Week.

NAPLES, Florida — Jennifer L. Seminerio, MD, spoke with Healio about key takeaways from her 2022 ACG/FGS Spring Symposium presentation, which focused on treatment for mild to moderate ulcerative colitis and Crohn’s disease.

Using a novel clinical pathway integrated into the electronic medical record, researchers were able to identify patients with inflammatory bowel disease who were overdue for medical follow-ups, according to data presented at the ACG Annual Scientific Meeting.

A 300-mg dose of anifrolumab provided clinically meaningful benefit and was generally well-tolerated among patients with systemic lupus erythematosus, regardless of previous exposure to biologic agents, according to data presented at ACR Convergence 2021.

Patients with psoriatic arthritis prefer oral over subcutaneous biologics, and prioritize complication avoidance and the ability to work and perform ordinary activities over clinical efficacy, according to data.

Biologic disease-modifying antirheumatic drugs used to treat juvenile rheumatic diseases are excluded entirely from national essential medicines lists in close to two-thirds of all countries in the world, according to data published in Pediatric Rheumatology.

Patients with psoriasis who received biologic drugs demonstrated a lower risk — that was statistically and clinically significant — for developing psoriatic arthritis, according to data published in Arthritis & Rheumatology.

Biologic therapies did not put individuals undergoing surgery at greater risk for post-operative skin and soft tissue infections, according to a study.

The use of biological disease-modifying antirheumatic drugs in patients with psoriasis reduces the risk for psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.